Schlagwort: XPhyto

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / October 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) („XPhyto“ or the „Company“) is pleased to report that it has signed a non-binding Letter

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) („XPhyto“ or the „Company“) is pleased to report a significant potential market opportunity for its oral dissolvable („ODF“)

VANCOUVER, BC and UTTENWEILER / ACCESSWIRE / June 8, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to report that Dr. Florian A. Sahr has joined its European operations as Head

VANCOUVER, BC, AND UTTENWEILER, GERMANY / ACCESSWIRE / May 9, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to provide a product development report on its Rotigotine transdermal („TDS“) patch, including

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 4, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) („XPhyto“ or the „Company“) is pleased to provide a market and product development report on

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / February 22, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to provide an update on its wholly owned subsidiary XPhyto Laboratories Inc. („XPhyto

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 24, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to provide an update on the integration of 3a-diagnostics GmbH („3a“) into XPhyto’s

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 17, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to announce the appointment of Mr. Drahoslav Zdarek as the Company’s Head of

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 10, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) („XPhyto“ or the „Company“) is pleased to announce two key appointments to continue its focus on research, development and

https://www.irw-press.at/prcom/images/messages/2021/60813/XPhytoArticleHealthEuropaTranslation.001.jpeg © iStock/Okan Celik 04. August 2021 – Das Biowissenschaftsunternehmen XPhyto Therapeutics hat kürzlich die Übernahme von 3a Diagnostics bekannt gegeben, um sein Angebot an Lösungen zur Infektionsprävention zu erweitern. Dieser Schritt ist die jüngste